NASDAQ:BNTC
Benitec Biopharma Limited Stock News
$9.60
-0.87 (-8.31%)
At Close: May 21, 2024
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
08:15am, Monday, 13'th May 2024
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April-
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
07:30am, Thursday, 18'th Apr 2024
-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide-
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
07:00am, Thursday, 18'th Apr 2024
HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
08:00am, Tuesday, 13'th Feb 2024
-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit- -Sec
Announcement marks the initiation of the first clinical trial conducted in human subjects employing Benitec's “Silence and Replace” DNA-directed RNA interference gene therapy platform Announcement
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
08:00am, Friday, 17'th Nov 2023
HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing nove
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
08:00am, Monday, 13'th Nov 2023
HAYWARD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing nove
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
08:00am, Thursday, 21'st Sep 2023
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
01:00pm, Friday, 11'th Aug 2023
HAYWARD, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
10:30pm, Tuesday, 08'th Aug 2023
HAYWARD, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023
01:00pm, Tuesday, 25'th Jul 2023
HAYWARD, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing nove
Benitec Biopharma to Present at the OPMD International Conference
08:05am, Monday, 08'th May 2023
HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing no
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
02:21pm, Tuesday, 18'th Oct 2022 Benzinga
Upgrades
According to Jefferies, the prior rating for Target Corp (NYSE:TGT) was changed from Hold to Buy. Target earned $0.39 in the second quarter, compared to $3.64 in the year-ago quarter. The cur
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
12:42pm, Friday, 16'th Sep 2022 GlobeNewswire Inc.
HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company devel
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
07:58am, Wednesday, 14'th Sep 2022 Benzinga
Gainers
Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX